Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Exciting new developments in the treatment of multicentric Castleman disease

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 19.12.13
Views: 4303

Prof Nikhil Munshi - Harvard Medical School, Massachussets, USA and Dr Raymond Wong - The Chinese University of Hong Kong

Speaking to ecancer from the 55th meeting of the American Society of Haematology (ASH) in New Orleans, USA, Prof Nikhil Munshi from Harvard Medical School, Massachusetts, USA, and Dr Raymond Wong from The Chinese University of Hong Kong discuss multicentric Castleman disease (MCD), a rare, potentially fatal, proliferative disorder, with a serious impact on quality of life.

Dr Wong discusses the challenges of diagnosis and treatment, and the investigations needed.  Prof Munshi emphasises the value of pathological confirmation of diagnosis, such as CT scan from neck to pelvis, to avoid misdiagnosis.

Dr Wong outlines the exciting results of the first multicentre, randomised, placebo-controlled trial with siltuximab - an anti-interleukin-6 monoclonal antibody - plus best supportive care, which were presented at ASH 2013. He describes how one third of people in the active arm achieved durable tumour response for at least 18 weeks, and one in four people had a complete resolution of the symptoms of MCD over this period.  He then describes how the drug also leads to an increase in haemoglobin level and a reduction in inflammatory parameters; he comments on the safety profile of siltuximab and its low infusion reactivity.

Prof Munshi discusses future treatment changes as a result of this trial, and notes that physicians now need to explore how to manage patients who do not respond to siltuximab.

Read our ASH 2013 conference report for free.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).



Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation